ABSTRACT
Introduction
Gliomas are a heterogeneous group of primary tumors in the central nervous system, and comprise 40 to 50% of all brain tumors. The most common type of gliomas are astrocytic tumors, a heterogeneous group of tumors, classified by degree of malignancy according to World Health Organization (WHO) criteria as diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) or glioblastomas (grade IV) 1 . Although glioblastomas may arise de novo, strong evidence indicates that some glioblastomas likely develop from low-grade astrocytomas; these tumors may also follow varying pathways of biological development 2 .
All of these histopathological types can recur, and can also be phenotypically malignant, depending on the location, patient's age, health status and the extent of surgical resection.
Though astrocytomas course of development can vary, the resulting outcome is frequently dismal, despite current therapeutic strategies. Astrocytomas infiltrate the brain diffusely, spreading throughout adjacent healthy tissues and recurring even after radical surgical resection 3 .
Microvessel proliferation is one of the most important criteria for diagnosing malignancy in diffusely infiltrating astrocytic tumors 4 . Characterizing the molecular pathways leading to glioma angiogenesis and progression has clinical relevance because blocking molecular pathways that drive angiogenesis has major therapeutic implications 5 . Because high-grade gliomas are highly vascularized tumors, targeting blood vessels with antiangiogenic agents seems to be a promising treatment pathway 6 .
Although the factors controlling glioma angiogenesis are not fully understood, experimental data support the concept that angiogenesis is required for glioma growth and that the process is driven primarily by tumor-secreted vascular endothelial growth factor (VEGF) 7, 8 . The formation of primitive blood vessels from progenitors like hemangioblasts and angioblasts is dependent on VEGF, which appears to play a major role in the angiogenesis of several other human tumors, such as colon and breast carcinomas 9 .
The majority of anti-angiogenic therapies already interfere with the VEGF pathway, and the results are even more encouraging when anti-VEGF antibodies are combined with chemotherapy. Trials targeting the VEGF-signaling pathways are currently under development 6 .
Besides VEGF, tyrosine kinase receptors, such as KIT, are also being investigated as having an important role in the cytogenetic alterations of angiogenesis process 8 . It is known that KIT, commonly present in juvenile brain tumors, also participate in glioma angiogenesis
The proto-oncogene KIT encodes CD117, a transmembrane tyrosine kinase that has a well-established role in several human tumors; cellular expression of CD117 has already been detected by immunohistochemistry in gliomas 10 . In addition to protein expression, it has also been suggested that KIT gene amplification may be observed more commonly in glioblastomas and astrocytic tumors than in oligodendrogliomas, which constitute gliomas outside the astrocytic lineage 11 . Therefore, the KIT amplification seems to be linked to the astrocytic tumors.
During angiogenesis, the KIT pathway as well as VEGF expression appears involved with astrocytoma growth, invasiveness and malignancy 11, 12 .
The degree of tumor vascularization can be measured by means of the microvessel density (MVD), which serves as an independent prognostic marker of survival in low-grade fibrillary astrocytomas 4, 13 . It has also been suggested that tumor angiogenesis and vascular density can be used as determinants of radiosensitization, of response to anti-angiogenesis drugs and as reliable prognostic markers 13, 14 .
Because Deparaffinized and rehydrated slides were subjected to heatinduced antigen retrieval for 15 minutes in a pressure cooker with 10 mM citrate buffer (pH 6.0) at 120 °C for CD34, or immersed in 10 mM citrate buffer (pH 6.0) during microwave heating at 700w
for 15 minutes for VEGF and KIT.
Evaluation of immunohistochemistry staining
Semiquantitative scores for VEGF and KIT were applied as following. Positive immunoreactions were categorized from 0 to 3 according to the extent and intensity of staining: grade 0 for no staining; grade 1 for weak focal staining; grade 2 for strong focal staining; and grade 3 for strong widespread staining.
VEGF and KIT antigen expressions were evaluated in the cytoplasm of neoplastic astrocytes. This graduated scale was adapted from Abduldrauf et al. 13 . For statistical analysis purposes, 0 and 1 were classified as negative, and grades 2 and 3 were grouped as positive.
Immunostained slides for CD34 were scanned field per field at 20x to facilitate the identification of positive reactions among vascular "hot spots". Microvessel counting was performed using a 100x magnification in two different fields at the site previously defined as the "hot spots". Images of these two fields were captured with a Digital Camera System DinoCapture, and the microvessels were manually identified using the free image processing and analyzing program Image Tool 3.00. If a discrepancy occurred in the number of vessels between the assessments of the two observers, the images were reassessed for a consensual analysis. MVD was expressed, in this study, as the number of vessels counted in the two hotspots.
Slides stained for CD34 were scanned at 20x for the identification of positive reactions. Two fields considered representative of vascularity were designated as vascular "hot spots". Images of the two hot spots were captured with a Digital Camera System DinoCapture using a 100x magnification, and the microvessels were identified and counted using the free image processing and analyzing program Image Tool 3.00. If a discrepancy occurred in the number of vessels between the assessments of the two observers, the images were reassessed for a consensual analysis. MVD was expressed, in this study, as the number of vessels counted in the two fields named as hot spots.
Statistical analysis
Statistical calculations were performed using SPSS 13.0 (SPSS Inc; Chicago, IL). In the case of a p<0.05, the result was VEGF expression in grades II and III astrocytomas and in glioblastomas is described in Table 1 . KIT expression was detailed in the same Table. In the vast majority of cases the expression for both markers, when
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Correlation of MVD with KIT and VEGF expression
The MVD was significantly higher for the group of tumors that expressed VEGF (p<0.005). The median MVD of the positive group was 34 (range 21-49), whereas the negative-for-VEGF group had a median of 23 (range 13-35), as illustrated in Figure 1 .
FIGURE 1 -Correlation between microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression (Mann-Whitney test).
MVD was also significantly higher for the group of tumors that expressed KIT (p<0.005). The median MVD of the positive group was 34 (range 27-49), whereas the negative for the KIT group had a median of 25 (range 13-39), as shown in Figure 2 . Tumor MVD was significantly associated with tumor grading (p<0.005), as shown in Figure 3 . Tumor microenvironments and genetic abnormalities that drive glioma growth, progression to malignancy and resistance to therapy are critical to optimize prognostic accuracy and to design optimal therapeutic strategies. Angiogenesis is fundamental for human reproduction and for wound healing, but it is also crucial for tumor progression, growth and metastasis. Angiogenesis is often present in high-grade lesions, and can be used as a prognostic factor. Many studies have focused on these characteristics and associations 16, 17 .
Leon et al. 16 reported rich angiogenic activity in gliomas.
Brain tumor growth was shown to depend largely on blood supply to provide nutrients and to remove necrotic debris from the central area of the neoplasm; a reciprocal relationship exists between the hemostatic system and tumor growth, cellular differentiation and metastasis. MVD is the final step of the whole process, and research dedicated to it allowed many authors to correlate certain tumors' biological aggressiveness with vascular proliferation 17 .
In our study, we found a strong relationship between vascular proliferation and tumor grade (p<0.005), which reinforces the importance of MVD status and glioma classification and prognosis because malignant astrocytoma progression is heralded and accompanied by increased angiogenesis 18 .
Usually, molecular control of the angiogenic process Sun and co-workers validated the hypothesis that KIT activation plays a fundamental role in glioma angiogenesis 27 . Its activation may promote these tumors' peculiar angiogenic patterns, which relate to gliomas' histopathological subtypes and vascular found that, contrary to earlier reports, KIT expression was seen in 32.5% (13/40) glioma cases with no association to tumor grade.
Those findings of KIT over-expression across low/high grades in glioma cases are similar to ours and suggest that it may not be a molecular abnormality accumulated during tumor progression.
Therefore, it is essential to elucidate whether the enhanced KIT expression is a cause or outcome of the glial neoplastic process 29 .
Conversely, conflicting reports suggest that tumor aggressiveness depends on an increased expression of KIT and its activated form 24 . Cetin et al. 10 studied a series of 52 glial tumors and found that 75% were positive for KIT, and the proportion of high-grade tumors was significantly greater than of low-grade tumors.
Conclusion
The vascular endothelial growth factor and KIT are markers associated with microvessel density and both VEGF and MVD correlated with grading. KIT had no significant relationship with grading in astrocytic tumors.
